USPSTF Recommends Early Screening for Syphilis in Pregnancy

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 19, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Nov. 19, 2024 -- The U.S. Preventive Services Task Force (USPSTF) recommends early screening for syphilis infection in all pregnant women (grade A recommendation). This recommendation forms the basis of a draft recommendation statement published online Nov. 19.

Researchers for the Agency for Healthcare Research and Quality in Rockville, Maryland, reviewed new evidence on the benefits and harms of screening and harms of treatment of syphilis infection in pregnant women to update the 2018 USPSTF recommendation. The researchers found that no new studies addressed the effectiveness of screening for reducing congenital syphilis or other adverse outcomes. The harms of screening were addressed in five studies with 51,118 participants; two studies with 130 participants addressed the harms of treatment. Index test positivity varied from 1.0 to 4.8 percent with respect to the harms of screening; false-positive estimates ranged from 0 to 65 percent, varying by screening algorithm and index test. The review did not address the accuracy of screening tests or comparative effectiveness of different screening algorithms.

Based on these findings and using a reaffirmation process, the USPSTF concludes with high certainty that screening asymptomatic pregnant persons for syphilis infection has a substantial net benefit. Consequently, the USPSTF recommends early screening for syphilis infection in all pregnant persons (grade A recommendation).

The draft recommendation statement and evidence review have been posted for public comment. Comments can be submitted from Nov. 19 to Dec. 23, 2024.

Draft Evidence Review

Draft Recommendation Statement

Comment on Recommendation Statement

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-11-20 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords